Totema is an antianemic drug Totema, a stimulant of hematopoiesis.
Release form and composition Totema:
Dosage form - oral solution: dark brown liquid, slight sediment is allowed, with a characteristic odor (10 ml each in glass (type III) double-ended yellow ampoules, 10 pcs. In a cardboard pallet, 2 pallets in a cardboard box) 1 ml of solution contains: active ingredients: iron (elemental, iron gluconate dihydrate) - 5 mg, copper (elemental, copper gluconate) - 0.07 mg, manganese (elemental, manganese gluconate) - 0.133 mg; auxiliary components: sucrose, dextrose (glucose), glycerol, polysorbate 80, anhydrous citric acid, sodium benzoate, sodium citrate dihydrate, tutti-frutti flavor, TPS caramel color (E150c), purified water.
Indications for use Totema:
- Prevention and treatment of iron deficiency anemias caused by the following
- bleeding; increased need for iron during pregnancy
- impaired absorption of iron or a deficiency in its intake with food.
- Contraindications anemia of non-ferrous deficiency
- thalassemia
- hemosiderosis
- hemochromatosis
- period of exacerbation of gastric ulcer and duodenal ulcer
- poisoning of the body with lead
- manganese
- copper
- Wilson-Konovalov disease
- syndrome of glucose-galactose malabsorption
- fructose intolerance, sucrase or isomaltase deficiency
- age up to 3 months
- hypersensitivity to the components of the drug.
- It is recommended to use the Totema solution with caution in patients with diabetes mellitus.
Method of administration and dosage Totema:
The solution is taken orally before meals. For safe opening of the ampoule, it is recommended to tear off a piece of cardboard from the package along the dotted line and bend it in half. After shaking the contents of the ampoule, break it on both sides and pour the solution into a glass with plain or sweetened water. Before starting treatment, it is necessary to determine the total iron-binding capacity of the serum and, during the use of the drug, to monitor it and the level of iron concentration in the blood serum at a frequency of 1 every 2 months. Recommended dosage: treatment: adults - 2-4 ampoules (100-200 mg) per day, children - at the rate of 5-7 mg per 1 kg of the child's weight per day, the dose received should be divided into 2-4 doses; prevention: adult patients and pregnant women (from the II trimester of pregnancy) - 1 ampoule per day. Children (depending on age) - from 1/4 to 1/2 of the daily therapeutic dose for adults. Treatment should be continued until the complete restoration of iron stores in the body, the average duration of the course is 3–6 months.
Side effects Totema:
from the digestive system:
pain in the epigastric region, nausea, heartburn, vomiting, constipation, diarrhea, stool staining black (not a pathology), darkening of tooth enamel; others: the development of allergic reactions.
special instructions Totema:
The effectiveness of treatment should be checked only 3 months after starting the use of the drug Totema. Tea reduces the absorption of iron, so excessive consumption should be avoided during treatment. To prevent the enamel of the teeth from darkening, the solution should be swallowed without holding it in the mouth or using a tube. Patients with diabetes mellitus must take into account that the content of sucrose in 1 ampoule is 3 g, and carbohydrates in a daily dose (4 ampoules) corresponds to 1 XE (bread unit). Taking Totema
can contribute to the staining of feces black, this is the norm for all iron preparations and does not need medical intervention. While taking the solution, fecal occult blood test indicators may be false positive. The negative effect of the drug Totema on the patient's ability to drive vehicles and mechanisms has not been established.
Drug interactions Totema:
While taking the Totema: tetracycline, ciprofloxacin, bisphosphonates, when administered orally, reduce their absorption; oxides, salts and hydroxides of aluminum, magnesium or calcium interfere with the absorption of iron salts, so the solution must be taken only 2 hours after taking these funds; other iron-containing agents, including those administered parenterally, cannot be use. Totema
